Adaptive Biotechnologies (ADPT) Set to Post Quarterly Earnings on Wednesday

Adaptive Biotechnologies (NASDAQ:ADPT) is projected to issue its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.0911) per share and revenue of $71.57 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The business had revenue of $71.55 million during the quarter, compared to the consensus estimate of $65.44 million. During the same quarter in the prior year, the business earned ($0.17) EPS. The company’s revenue was up 21.5% on a year-over-year basis. On average, analysts expect Adaptive Biotechnologies to post ($0.40) EPS for the current fiscal year and ($0.19) EPS for the next fiscal year.

Adaptive Biotechnologies Trading Up 5.3%

Shares of ADPT stock opened at $27.66 on Wednesday. The business’s 50 day moving average is $26.22 and its two-hundred day moving average is $19.47. Adaptive Biotechnologies has a twelve month low of $12.00 and a twelve month high of $30.74.

Insider Activity

In other Adaptive Biotechnologies news, COO Julie Rubinstein sold 11,881 shares of the business’s stock in a transaction that occurred on Monday, October 26th. The shares were sold at an average price of $26.04, for a total transaction of $309,381.24. Following the completion of the sale, the chief operating officer directly owned 377,802 shares in the company, valued at $9,837,964.08. The trade was a 3.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Susan Bobulsky sold 6,444 shares of the company’s stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $30.00, for a total transaction of $193,320.00. Following the sale, the insider directly owned 389,350 shares of the company’s stock, valued at approximately $11,680,500. This trade represents a 1.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,016,419 shares of company stock valued at $25,879,607 in the last 90 days. 5.70% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on ADPT shares. Piper Sandler boosted their price target on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. National Bank Financial set a $34.00 target price on Adaptive Biotechnologies in a report on Tuesday, September 22nd. TD Cowen boosted their target price on shares of Adaptive Biotechnologies from $28.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. The Goldman Sachs Group assumed coverage on Adaptive Biotechnologies in a research note on Tuesday, September 29th. They issued a “buy” rating and a $35.00 price objective for the company. Finally, Guggenheim lifted their price objective on Adaptive Biotechnologies from $25.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $30.06.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and research tools. Based in Seattle, Washington, the company analyzes immune-cell receptors to help identify and measure disease, support drug development and improve understanding of immune responses.

Adaptive’s products include clonoSEQ, a clinical assay used to detect and monitor measurable residual disease in certain blood cancers, including multiple myeloma, acute lymphoblastic leukemia and chronic lymphocytic leukemia.